osemitamab (TST001)

News alerts, weekly reports and conference planners

Company:

Transcenta

Drug class:

CLDN18.2 inhibitor

Related drugs:

CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3
CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3

Associations
(2)